Phase II study of ametantrone in a human tumor cloning assay.
The anticancer activity of ametantrone was investigated in a human tumor cloning assay. Tumor samples were freshly obtained from 105 patients. Cells were exposed for 1 hr to drug concentrations of 1 and 10 micrograms/ml. A reduction in the number of tumor colony-forming units by 50% or more was seen in 2/31 breast cancers, 2/25 ovarian cancers, 1/10 primaries of unknown origin, 1/10 melanomas, 2/8 non-small cell lung cancers, 1/5 small cell lung cancers and 1/3 colon cancers. Only three of these in vitro responses were consistently obtained at the probably more relevant concentration of 1 microgram/ml. These findings indicate that low efficacy should be expected in cancer patients with ametantrone. The predictive value of these in vitro phase II data remains to be demonstrated.
D000880:Anthraquinones / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008942:Mitoxantrone / Q000031:analogs & derivatives*; D009369:Neoplasms / Q000473:pathology; D014411:Neoplastic Stem Cells / Q000187:drug effects*; D013234:Stem Cells / Q000187:drug effects*; D014410:Tumor Stem Cell Assay
D000880:Anthraquinones; D004317:Doxorubicin; D008942:Mitoxantrone; C020182:ametantrone